文献速递创伤与烧伤复苏、休克与脓毒症

四因子凝血酶原复合物浓缩物不劣于andexanet alfa用于逆转口服Xa因子抑制剂:东部创伤外科协会多中心研究

Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
PubMed 文献 · J Trauma Acute Care Surg · 2024-04-30
一句话结论在服用DOAC的创伤患者中,四因子PCC逆转治疗的输血需求不劣于andexanet alfa(基于10中心263例回顾性数据)。

本研究为回顾性、非劣效性多中心研究,纳入2018年7月1日至2019年12月31日期间服用DOAC 12小时内受伤、需输注红细胞或存在创伤性脑损伤的成人患者,比较四因子PCC与andexanet alfa的逆转效果。主要终点为浓缩红细胞输注单位数,非劣效界值为2单位。共纳入10个中心263例患者,77例(29%)接受PCC,186例(71%)接受AA。两组输血率相近(AA 23.7% vs PCC 19.5%),中位输血量均为0单位。校正协变量后,PCC较AA的输血量率比为1.02(95%CI 0.79-1.33),估计增加0.123单位(95%CI 0.53-2.02),符合非劣效。作者认为PCC在创伤患者DOAC逆转方面不劣于AA,但需前瞻性随机试验进一步比较。

要点

  • 在服用DOAC 12小时内受伤、需输血或合并TBI的成人创伤患者中,四因子PCC的输血需求不劣于andexanet alfa(非劣效界值2单位)。
  • 10中心263例中,77例(29%)接受PCC、186例(71%)接受AA;两组输血率AA 23.7% vs PCC 19.5%,中位输血量均为0单位。
  • 校正后PCC较AA的输血量率比为1.02(95%CI 0.79-1.33),估计增加0.123单位(95%CI 0.53-2.02),未超过2单位非劣效界值。
  • 作者认为PCC似乎不劣于AA,但需前瞻性随机试验进一步比较两者对服用DOAC的创伤患者出血的治疗效果。

适用人群与场景

  • 成人创伤患者,服用DOAC(apixaban或rivaroxaban)后12小时内受伤,且需输注红细胞或存在创伤性脑损伤,并接受了AA或PCC逆转治疗。

诊断标准与关键阈值

  • DOAC使用定义为受伤前12小时内服用apixaban或rivaroxaban。
  • 非劣效界值:两组红细胞输注量差异2单位。

研究设计与关键结果

  • 研究类型:回顾性、非劣效性多中心研究;10个中心,263例患者;PCC组77例(29%),AA组186例(71%)。
  • 主要终点:两组输血率AA 23.7% vs PCC 19.5%,中位输血量均为0单位;校正协变量后,PCC较AA的输血量率比1.02(95%CI 0.79-1.33),估计增加0.123单位(95%CI 0.53-2.02)。
  • 非零输血组平均输血量为6.13单位。
  • 缺失数据采用MICE插补,零膨胀泊松回归用于处理零输血单位过多的情况。

证据类型、等级与局限

  • 证据类型:回顾性多中心非劣效性研究;证据等级:Level III(治疗/临床管理)。
  • 局限:原文报告需进一步前瞻性随机试验比较PCC与AA治疗服用DOAC的创伤患者出血。

对床旁实践的改变

  • 作者认为,PCC在创伤患者DOAC逆转方面似乎不劣于AA(基于红细胞输注需求);但需前瞻性随机试验进一步比较两者对服用DOAC的创伤患者出血的治疗效果。

指南或共识出处

  • 东部创伤外科协会(Eastern Association for the Surgery of Trauma)多中心研究

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Andexanet alfa (AA) is the only FDA-approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with four-factor prothrombin complex concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing noninferiority of PCC.

METHODS: We performed a retrospective, noninferiority multicenter study of adult patients admitted from July 1, 2018, to December 31, 2019, who had taken a DOAC within 12 hours of injury, were transfused red blood cells (RBCs) or had traumatic brain injury, and received AA or PCC. Primary outcome was PRBC unit transfusion. Secondary outcome with intensive care unit length of stay. MICE imputation was used to account for missing data and zero-inflated Poisson regression was used to account for an excess of zero units of RBC transfused. Two units difference in RBC transfusion was selected as noninferior.

RESULTS: Results: From 263 patients at 10 centers, 77 (29%) received PCC and 186 (71%) AA. Patients had similar transfusion rates across reversal treatment groups (23.7% AA vs. 19.5% PCC) with median transfusion in both groups of 0 RBC. According to the Poisson component, PCC increases the amount of RBC transfusion by 1.02 times (95% confidence interval, 0.79-1.33) compared with AA after adjusting for other covariates. The average amount of RBC transfusion (nonzero group) is 6.13. Multiplying this number by the estimated rate ratio, PCC is estimated to have an increase RBC transfusion by 0.123 (95% confidence interval, 0.53-2.02) units compared with AA.

CONCLUSION: PCC appears noninferior to AA for reversal of DOACs for RBC transfusion in traumatically injured patients. Additional prospective, randomized trials are necessary to compare PCC and AA for the treatment of hemorrhage in injured patients on DOACs.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Estroff JM, Devlin J, Hoteit L, et al. Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study. J Trauma Acute Care Surg. 2024. PMID: 38685190. doi:10.1097/TA.0000000000004345

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。